Decreased CD$^8^+$CD$^{28^+}$/CD$^8^+$CD$^{28^-}$ T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease

Shi-xue Dai, MD, PhD$^a$, Hong-xiang Gu, MD, PhD$^b$, Qian-yan Lin, BS$^c$, Yan-kun Wu, BS$^d$, Xiao-yan Wang, BS$^d$, Shao-zhuo Huang, BS$^c$, Tao-si Xing, PhD$^h$, Min-hua Chen, BS$^f$, Qing-fang Zhang, MS$^a$, Zhong-wen Zheng, MS$^a$, Wei-hong Sha, MD, PhD$^a$.

Abstract

Crohn disease (CD) with complications such as penetrating, strictureting, and perianal disease is called complicated CD. The aim of this study is to test the efficiency with which the CD$^8^+$CD$^{28^+}$/CD$^8^+$CD$^{28^-}$ cell balance can predict a subsequent active stage in patients with newly diagnosed complicated CD.

Seventeen patients with complicated CD and 48 CD patients with no complications were enrolled. Blood CD$^8^+$ T cells were tested from all of the 65 newly diagnosed CD patients upon enrollment. The potential risk factors were compared between the 2 groups. A 30-week follow-up was performed, and the efficiency of the CD$^8^+$ T cell balance at predicting active CD was analyzed using receiver-operating characteristic curves. The cumulative remission lasting rates (CRLRs) were analyzed using the Kaplan–Meier method.

Compared with the control CD group, patients with complicated CD were predominantly male and younger in age; they also had lower body mass indices (BMIs), higher Crohn disease activity indices (CDAIs), higher immunosuppressant and steroid prescription rates, and significantly higher surgical rates. The CD$^8^+$CD$^{28^+}$/CD$^8^+$CD$^{28^-}$ balance was associated with BMI, CDAI, steroids, and surgery. The CD$^8^+$CD$^{28^+}$/CD$^8^+$CD$^{28^-}$ ratios were significantly lower at week 0 and on the 6th, 22nd, and 30th week during follow-up with a shorter lasting time of remission for the complicated CD patients. The CD$^8^+$CD$^{28^+}$/CD$^8^+$CD$^{28^-}$ ratio could accurately predict the active stage for the patients with complicated CD, and the highest sensitivity (89.2%) and specificity (85.3%) were found when the ratio was 1.03. Treatment with steroids and surgery, along with a significantly lower CD$^8^+$CD$^{28^+}$/CD$^8^+$CD$^{28^-}$ ratio and lower CRLRs, was closely related to a worse outcome for the patients with complicated CD.

Patients requiring steroids and surgery experience more severe disease activity and thus a disequilibrated immunological balance, which could be the main reason for a decreased CD$^8^+$CD$^{28^+}$/CD$^8^+$CD$^{28^-}$ ratio. This ratio can sensitively predict the active stage for patients with complicated CD, and more care should be taken when this ratio is <1.03.

Abbreviations: BA = biological agent, CD = Crohn disease, CRLRs = cumulative remission lasting rates, IBD = inflammatory bowel disease, LTR = lasting time of remission, ROC = receiver-operating characteristic, UC = ulcerative colitis.

Keywords: CD$^8^+$ T cells, complication, Crohn disease, immunological balance, prognosis prediction

1. Introduction

Significant changes have been witnessed in the geographical distribution of inflammatory bowel disease (IBD); IBD has shifted from the developed world, with a high incidence rate, to traditionally low-incidence regions such as Asia, South America, Southern and Eastern Europe.[1] The incidence rate is estimated to be 1.37 per 100,000 individuals in Asia and 3.44 per 100,000 individuals in China, which has the highest IBD incidence in Asia,[2] emphasizing the need for specific health care resources in developing countries.

However, Crohn disease (CD) is more difficult to diagnose than ulcerative colitis (UC) because of CD’s atypical and nonspecific clinical manifestations. Thus, many CD cases,
approximately 52% in Asia, are finally diagnosed upon the appearance of parenteral complications, including penetrating, stricture, perianal disease, intrauterine abortion, or other parenteral manifestations; these cases are classified as complicated CD.[5] Almost all gastroenterologists attempt to find biomarkers or risk-prediction models to aid in early diagnosis and prognosis prediction for CD. However, no validated, inexpensive, or sensitive models for the prediction of risk are available for complicated CD.[13] Increasing evidence shows that T cells, including CD4+ and CD8+ T cells and especially regulatory T cells [Tregs, mainly consisting of CD4+CD25+[4] and CD8+CD28−T cells[3]], play a primary role in the immunologic pathogenesis of IBD, and thus we believe that T cell subsets will be ideal biomarkers in prognosis prediction for complicated CD.

Owing to the core position of Tregs in IBD,[8] we have focused on CD8− Tregs, which are less commonly investigated than CD4+CD25+ Tregs. Our previous study showed that the balance of circulating CD8+CD28− and CD8−CD28+ T cells, as well as the CD8+CD28−/CD8+CD28+ ratio, played a critical role in intestinal immunity, suggesting that a high level of blood CD8+CD28− T cells is favorable for both patients and rats with UC.[6,7] Furthermore, we hypothesized that the CD8+CD28−/CD8+CD28+ ratio plays a significant role in prognosis; thus, we arranged a follow-up for the patients with complicated CD at 30 weeks after diagnosis. We expected that the initial CD8+CD28−/CD8+CD28+ ratio could predict poor outcome with high sensitivity and specificity for the complicated CD patients. This study was conducted as follows.

2. Methods

2.1. Clinical data

Our investigation was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University. The CD patients, with clinical diagnoses according to the local endoscopy, pathology, and pharmacy records,[8] came from the Gastroenterology and Emergency departments of Nanfang Hospital, Southern Medical University, as well as the Department of Gastroenterology, Guangdong General Hospital and Guangdong Academy of Medical Sciences, between October 2013 to December 2016. CD patients with tumors, tuberculosis, autoimmune diseases, pregnancy[9] or poor compliance were excluded.[10] Overall, 65 CD subjects were enrolled in this study, ranging in age from 12 to 61 years. The study participants included 17 complicated (the observation group) and 48 common (the control group) CD subjects, 46 males and 19 females. There were 8 cases who mainly suffered from penetrating (8/65, 12.31%), 12 from strictureing (12/65, 18.46%), and 6 from perianal diseases (6/65, 9.23%); 3 from ankylosing spondylitis (3/65, 4.62%); and 1 from uveitis (1/65, 1.54%); 7 patients experienced at least 2 of the above-mentioned 3 complications (7/65, 10.77%).

2.2. Risk factor comparison

We compared the internal factors,[11] including sex, age, course of disease, body mass index (BMI), Crohn disease activity index (CDAI), and family history of bowel diseases, between the complicated and control CD groups. The external factors[12] (mainly therapeutic factors) assessed included 5-aminosalicylic acid (5-ASA), immunosuppressants, steroids, probiotics, biological agents (BAs), and surgery after definite diagnosis.

2.3. Flow cytometry evaluation of CD8+T cells

CD8-FTIC and CD28-PE antibodies (Santa Cruz Biotechnology, Dallas, TX) were applied to label specific circulating T cells.[13] Peripheral blood was drawn after definite diagnosis for CD8+ T cell frequency testing. The antibody-labeled blood samples were washed and fixed, and then the cells were detected by flow cytometry (FCM) using a Beckman Coulter Epics XL flow cytometer and System II software (Beckman Coulter, Pasadena, CA).[14,15] FCM was also used to measure the percentages and fluorescence intensities of the immunostained CD8+CD28− and CD8−CD28+ T cells in the sample. For each measurement, 20 × 10^4 cells were counted.[16]

2.4. Follow-up and prognosis prediction

A 30-week follow-up was performed and CD8+ T cells were evaluated at the end of week 0 (before definite CD diagnosis) and the 6th, 22nd, and 30th week after diagnosis (concomitantly with the infliximab time points regardless of whether the CD patients used infliximab) for all 65 CD patients. The quantities of CD8+CD28− T cells, CD8−CD28+ T cells, and the CD8+CD28−/CD8−CD28+ ratio were compared between the complicated and control CD patients at the above-mentioned 4 time points. The sensitivity and specificity of the initial (0 week) measurements of the CD8+CD28− T cells, CD8−CD28+ T cells, and CD8+CD28−/CD8−CD28+ ratio in predicting the outcome were analyzed using receiver-operating characteristic (ROC) curves. The last time of remission (LTR) was calculated for the CD patients after they were determined to be in the active stage by both clinical manifestations and laboratory examinations. The cumulative remission lasting rates (CRLRs) under the different risk factors were evaluated after follow-up.

2.5. Statistical analysis

Repeated measures analysis of variance was used to compare the CD8+ T cells and their balance at different time points, and Spearman or Pearson analyses were performed to identify the correlations between CD8+ T cells and risk factors. ROC curves were used to verify the predicting model for CD8+ T cells and their balance, and the CRLRs were analyzed using the Kaplan-Meier method. The analysis was performed using the statistical software package SPSS 17.0, and statistical significance was defined at P < .05.

3. Results

3.1. Complicated and common CD present different risk factors

There was no significant difference in the course of the disease, stage, family history of bowel diseases, administration of 5-ASA, probiotics, or BA between the complicated and control CD cases (all P > .05). Compared with the control CD group, patients with complicated CD were more commonly male and younger in age; they also had lower BMIs, higher CDAIs, higher prescription rates for immunosuppressants and steroids, and a significant higher surgical rate (Table 1).

3.2. The CD8+T cell balance is correlated with risk factors

Spearman or Pearson analysis showed that the average (from week 0 to the 30th week) number of CD8+CD28− T cells and
CD8+CD28− T cells and the CD8+CD28+/CD8+CD28− ratio were negatively correlated with CDAI, steroids, and surgery (all P < .05). However, only the CD8+CD28−/CD8+CD28+ ratio, but not CD8+CD28+ or CD8+CD28− T cells, was positively correlated with BMI (P = .001, .324 and .363, respectively; Table 2).

### 3.3. The CD8+CD28−/CD8+CD28+ ratio changed in opposite directions between the complicated and control CD patients during follow-up: the ratio apparently rose with time in the control CD group but slightly decreased in the complicated CD group. At all time points (weeks 0, 6, 22, and 30), the differences in CD8+CD28− T cells, CD8+CD28− T cells, and CD8+CD28−/CD8+CD28− were significant between the complicated and control CD groups (all P < .05, Fig. 1).

### 3.4. CD8+CD28−/CD8+CD28+ balance can effectively predict the poor outcome

Higher initial (before definite CD diagnosis) CD8+CD28− T cell levels and CD8+CD28−/CD8+CD28− ratios were found in the CD group experiencing subsequent remission (n = 54, including 13 in the complicated and 41 in the control groups) when compared to the group subsequently experiencing active CD (n = 11, including 4 in the complicated group [1 case with enterovesical fistulas] and 7 in the control group; P < .0001 and P = .001, Fig. 2A and C), but the opposite was found for CD8+CD28− T cells (P = .045, Fig. 2B). The LTR of the complicated group was (22.46 ± 9.02) weeks, which was significantly shorter than in the control group (30.10 ± 14.75 weeks; P = .044); LTR was correlated with CD8+CD28− T cells, CD8+CD28− T cells, and the CD8+CD28−/CD8+CD28+ ratio (P = .002, < .0001, and < .0001, respectively). Statistical significance was found for the initial CD8+CD28− T cell and CD8+CD28− T cell levels as well as the CD8+CD28−/CD8+CD28+ ratio for predicting the subsequently active stage in both complicated and control CD patients, with area under ROC curve (AUC) of 0.802, 0.338, and 0.890, respectively (95% CIs were 0.697–0.907, 0.206–0.470, and 0.822–0.958, respectively, and P < .0001, P = .042 and P < .0001, respectively; Table 3 and Fig. 2D). The cutoff value showed that the best sensitivity (89.26%) and specificity (85.32%) were found when the ratio was 1.03 (9.38% CD8+CD28− T cells/9.11% CD8+CD28− T cells).

### Table 1
Comparison of factors between complicated and control CD (N = 65 total).

| Factors                        | Classification | Complicated CD (n = 17) | Control CD (n = 48) | Statistics | P       |
|--------------------------------|----------------|-------------------------|---------------------|------------|---------|
| Sex                            | Male           | 14 (82.35%)             | 32 (66.67%)         | χ² = 12.138 | .001    |
|                                | Female         | 3 (17.65%)              | 16 (33.33%)         |            |         |
| Age, y                         | 24.55 ± 7.30   | 28.56 ± 7.13            | t = −2.389          | .019       |         |
| BMI                            | 15.94 ± 2.56   | 18.63 ± 2.68            | t = −4.107          | < .0001    |         |
| CDAI                           | 454.29 ± 39.57 | 217.36 ± 90.73         | t = 12.488          | < .0001    |         |
| Course of disease, y           | 5.71 ± 3.52    | 4.98 ± 2.87             | t = 0.825           | .412       |         |
| Stage before definite diagnosis| Remission      | 1 (5.88%)               | 7 (14.58%)          | Z = −0.931 | .439    |
|                                | Active         | 16 (94.12%)             | 35 (72.92%)         |            |         |
| Family history of bowel diseases| Yes           | 5 (29.41%)              | 13 (27.08%)         | χ² = 0.034 | .543    |
|                                | No             | 12 (70.59%)             | 35 (72.92%)         |            |         |
| 5-ASA before definite diagnosis| Yes           | 15 (88.24%)             | 41 (85.42%)         | χ² = 0.864 | .566    |
|                                | No             | 2 (11.76%)              | 7 (14.58%)          |            |         |
| Immunosuppressant before definite diagnosis | Yes | 16 (94.12%) | 32 (66.67%) | χ² = 4.898 | .029    |
|                                | No             | 1 (5.88%)               | 16 (33.33%)         |            |         |
| Steroids before definite diagnosis| Yes         | 11 (64.71%)             | 44 (81.67%)         | Z = −2.627 | .015    |
|                                | No             | 6 (35.29%)              | 8 (18.33%)          |            |         |
| Probiotics before definite diagnosis | Yes        | 10 (58.82%)             | 26 (54.17%)         | χ² = 0.110 | .483    |
|                                | No             | 7 (41.18%)              | 22 (45.83%)         |            |         |
| BA use after diagnosis         | Yes           | 14 (82.35%)             | 35 (72.92%)         | Z = 0.770  | .528    |
|                                | No             | 3 (17.65%)              | 13 (27.08%)         |            |         |
| Surgery after diagnosis        | Yes           | 8 (47.06%)              | 0 (0.00%)           | Z = −5.036 | < .0001 |
|                                | No             | 9 (52.94%)              | 48 (100.00%)        |            |         |

5-ASA = aminosalicylic acid, BA = biological agent, BMI = body mass index, CD = Crohn disease, CDAI = Crohn disease activity index.

### Table 2
Correlation of essential risk factors with average CD8+ T cells and their balance.

| Factors     | CD8+CD28− T cells | CD8+CD28− T cells | CD8+CD28−/CD8+CD28+ |
|-------------|-------------------|-------------------|---------------------|
| Sex         | −0.158 (.128)     | 0.008 (.940)      | −0.096 (.359)       |
| Age         | −0.020 (.846)     | −0.079 (.447)     | 0.026 (.834)        |
| BMI         | 0.103 (.324)      | 0.095 (.363)      | 0.337 (.001)        |
| CDAI        | −0.283 (.006)     | 0.245 (.017)      | −0.309 (.002)       |
| Immunosuppressant | 0.162 (.119) | 0.146 (.161) | −0.026 (.805) |
| Steroids    | −0.469 (.000)     | 0.368 (.000)      | −0.470 (.000)       |
| Surgery     | −0.260 (.011)     | 0.226 (.029)      | −0.270 (.009)       |

BMI = body mass index, CDAI = Crohn disease activity index.
3.5. **CD patients with different risk factors had different outcomes**

Tests showed that CD8+CD28+ T cells and the CD8+CD28+/CD8+CD28− ratio were significantly higher in the nonsteroid and nonsurgery patients than in those receiving steroids or undergoing surgery (all \( P > .05 \); Fig. 3A, C, D, and F), whereas the CD8+CD28− T cell levels were significantly lower in the nonsteroid and nonsurgery patients than in those receiving steroids or undergoing surgery (\( x^2 = 23.498 \) and 8.561, respectively, and \( P < .0001 \) and \( P = .003 \), respectively; Fig. 4A and B).

![Figure 1](image1.png)

**Figure 1.** The frequencies of CD8+ T cells and their balance during follow-up in complicated and control CD patients. (A, B, and C depict CD8+CD28+ T cells, CD8+CD28− T cells, and CD8+CD28+/CD8+CD28−, respectively; a represents \( P < .05 \) when compared to week 0, whereas c represents \( P < .05 \) in complicated compared to control CD patients.).

![Figure 2](image2.png)

**Figure 2.** The frequencies and balance of CD8+ T cells in patients under remission and active Crohn disease (CD) patients before definite diagnosis (A, B, and C) and the receiver-operating characteristic (ROC) curves evaluating the ability of CD8+ T cells and their balance to predict the active stage in complicated and control CD patients (D). The diagonal line in D is the diagnostic reference line.
4. Discussion

4.1. Epidemiology and risk factors of CD complications

It has been reported that the natural history of CD includes rates of complicated disease ranging from 48% to 52% at 5 years after diagnosis.[14] An Asian study[2] revealed that there has been a 2-3-fold increase in IBD incidence in several countries in Asia, and complicated and penetrating CD cases are more common in Asia than in western countries. A Chinese study[15] also indicated that the clinical features of IBD in China were different from those in developed countries, regardless of age and sex distribution, disease location and severity, or the prevalence of extraintestinal manifestations. A total of 11 of 65 (16.92%) CD patients in our study were younger than 18 years, and 17 of 65 (26.15%) subjects suffered from complications, with an average disease course of 5.3 years in our study, which was not as severe as the CD cases in the United States.[16]

Pathologically, stricturing generates when regeneration and repair fail to restore normal tissue architecture (as in the case of the older female with enterovesical fistulas in Fig. 5), and intestinal wall thickening can cause luminal narrowing.[17] However, what clinical factors cause IBD and its complications remain unknown.[18] To gain better understanding of the risk factors, we classified them into 2 types: internal and external factors. The internal factors include sex, age, age at onset, course of disease, stage, and family history, BMI, and CDAI,[19] whereas the external factors often contain therapeutic factors, such as the administration of 5-ASA, immunosuppressants, steroids, BAs, and surgery.[12,20] We found that no significant differences existed in the course of disease, stage, family history of bowel diseases, administration of 5-ASA, probiotics, and BA between complicated and control CD, indicating that these factors could not accelerate or retard the emergence of complications. Conversely, we found that male sex, younger age, lower BMI, higher CDAI, and higher rates of immunosuppressants, steroids and surgery were the distinguishing characteristics between the 2 groups, indicating that young and thin male CD patients are more prone to complications, consistent with Jacobsen et al’s findings.[21]

Regarding therapeutics after definite CD diagnosis, BAs are the preferred medications if the patients have indications,[22] which is the main reason why we chose weeks 0, 6, 22, and 30, corresponding to the infliximab prescription schedule, as the time points for follow-up. In our study, 49 of 65 (75.38%) subjects received infliximab, and the remaining 16 (24.62%) subjects did not undergo infliximab treatment because of financial difficulties. Unfortunately, 9 of these 16 (56.25%) cases progressed to an active stage within 30 weeks after definite diagnosis, indicating the vital therapeutic effect of BA during a short time period, which differed slightly from Lichtenstein et al’s report.[23] This long-term cohort study found that the mortality was similar between patients with infliximab treatments and those receiving

Table 3

| Variables                        | AUCs  | Std. error | Asymptotic sig. | Lower Bound | Upper Bound |
|----------------------------------|-------|------------|-----------------|-------------|-------------|
| CD8⁺CD28⁺ T cells                | 0.802 | 0.054      | <0.0001         | 0.697       | 0.907       |
| CD8⁺CD28⁻ T cells                | 0.338 | 0.067      | 0.042           | 0.206       | 0.470       |
| CD8⁺CD28⁺/CD8⁺CD28⁻              | 0.890 | 0.036      | <0.0001         | 0.822       | 0.958       |

AUCs = areas under curves, CD = Crohn disease.

Figure 3. CD8⁺ T cells in nonsteroid/nonsurgery patients (No) and patients receiving steroids or undergoing surgery (Yes). A, B, and C represent comparisons between patients receiving steroids or not, whereas D, E, and F represent comparisons between patients undergoing surgery or not.
other treatments only, whereas an increased risk of serious infection was observed with infliximab. Based on these data, we think that BAs are essential for newly diagnosed CD subjects, especially for those with complicated CD, regardless of whether they undergo surgery.

4.2. CD8+ T cells are vital in IBD follow-up

Similar to CD4+ T helper (Th) cells, CD8+ T effector (Teff) cells are the other important T lymphocyte subset that can mount both local and systemic immune responses in IBD pathogenesis.[24] In mucosal immune responses, normal intestinal epithelial cells, the unique non-dendritic cell, non-monocyte, or non-B cell specialized antigen presenting cells (APCs), could express major histocompatibility complex class II molecules constitutively, expressing some critical costimulatory molecules, such as gp180,[25] to activate certain peripheral blood CD8+ T cells selectively for a suppressor function.[26,27] Furthermore, Raffaello et al.[28] have demonstrated for the first time that not only can circulating CD8+CD28− suppressor T cells (Ts) be involved in the differentiation of tolerogenic APCs, but they can also suppress the Th cell response via contact mediated by APCs, implying that CD8+CD28− suppressor T cells participate in the maintenance of peripheral tolerance. It has been confirmed that a lack of suppressor T cells (including CD8+CD28− T cells) induced by intestinal epithelial cells is relevant to IBD.[29] These data agree with Allez et al.'s[30] finding that mucosal CD8+CD28− T cells can function in anti-inflammatory roles, inhibiting the superabundant immunological reaction to protect the intestinal mucosa from pathological injuries, and CD8+CD28+ T cells can

Figure 4. Survival plots of Crohn disease patients with or without steroid and surgery treatments. (The abscissa represents the lasting time of remission [LTR], whereas the ordinate represents the cumulative remission lasting rates. A and B depict patients receiving steroids and surgery, respectively.) (A) The median LTR of the nonsteroid group was 36.14 weeks, with a 95% confidence interval [CI] of 34.35–37.92, whereas the median LTR in the steroid group was 27.48 weeks, with a 95% CI of 23.01–31.95. B: The median LTR of the nonsurgery group was 35.09 weeks, with a 95% CI of 33.30–36.89, whereas the median LTR for the surgery group was 27.90 weeks, with a 95% CI of 20.26–35.54.

Figure 5. Computed tomography (CT) and magnetic resonance imaging (MRI) scanning images of a 58-year-old female with complicated Crohn disease. This patient presented with abdominal pain for >10 years, with a 3-month history of cloudy urine. Enhanced CT scanning showed a nidus with wall edema and mucosal thickness in the far end of the ileum (arrows in A), and the nidus invaded the bladder and shaped an eminence lesion, with a size of 38 × 23 mm (B). MRI scanning showed a mass convex to the enteric cavity of the ileum, with tressis and internal fistula (T2-weighted, C), and this inflammatory mass encroached on the anterosuperior bladder (T1-weighted, D).
differentiate into CD8+CD28- T cells to maintain active immune suppression.

Two possible mechanisms exist for how CD8+ T cells are involved in controlling IBD. In one mechanism, after expressing CD8α upon arrival at the intestinal epithelium, CD4+ T cells, with double-positive expression, could upregulate the production of interleukin (IL)-10 by suppressing TH1 on the NF-κB-GATA-10-dependent manner. [12] Recent studies have shown that subsets of CD8+ T cells, Foxp3-expressing Tregs were detected on the lamina propria (LP) of patients with IBD at a higher level than in healthy controls, whereas IL17-expressing Th17 cells were higher in patients with UC than in healthy individuals. Compared with LPMCcs, both Tregs and Th17 were higher in the PBMCs of IBD patients, indicating that the plasticity in patients with IBD is led by distinct CD8+ T cells.[13]

It can be concluded from this literature that CD8+ T cells and their balance are vital in IBD. However, our findings seem to contradict the above-mentioned data. We found that the CD8+CD28+/CD8+CD28- equilibrium changed inversely between complicated and control CD patients, particularly at the end of the 30th week, during follow-up: the ratio rose with time in the control CD group but declined in the complicated CD group. Moreover, at all of the time points (weeks 0, 6, 22, and 30), the CD8+CD28+/CD8+CD28- ratios were significantly lower in complicated CD patients than in control CD patients. Surprisingly, it seemed that lower CD8+CD28+/CD8+CD28- ratios were related to a worse outcome. The measurements were taken at the end of the 6th week during follow-up, during the expectant completion of the induced remission stage.[20,23] In the control CD patients, the CD8+CD28+/CD8+CD28- ratios increased at the end of the 22nd and 30th weeks, the time points belonging to the remission stage for most patients, which was in line with expectations. However, the ratios still decreased at these 2 time points for the complicated CD patients, indicating a more severe immunologic dysfunction caused by the complications.[34]

Penetrating, structuring, and anal fistula signify that more CD8+CD28- T cells, the main force to suppress mucosal immunity, will be consumed, and more time will thus be required to increase the frequencies of CD8+CD28+ T cells, which are derived from CD8+CD28+ T cells.[7,35] 4.3. The CD8+CD28+CD8+CD28- ratio can effectively predict the active stage of CD

Funderburg et al.[36] found that the plasma levels of IL-6, interferon-γ, and activated CD8+ T cells were increased in IBD patients compared with healthy controls, drawing an association between CD8+ T cell subsets and their cytokines. Although many studies were conducted to find a perfect biomarker that is helpful in the evaluation of IBD disease activity, the prognostic efficiency is not satisfactory, and an ideal prediction model has not yet been established.[37,38] Based on the background, we turned to an immunological balance, the CD8+CD28+CD8+CD28- ratio, to validate a more powerful prediction model.

We found that a significantly lower initial CD8+CD28+CD8+CD28- ratio was found in the patients with subsequent active CD than in those with subsequent remission, indicating that CD relapse is associated with a decreased CD8+CD28+/CD8+CD28- ratio. Because the lasting time of remission (LTR) can directly reflect the prognosis for IBD patients,[139] and because the patients with complicated CD had a significant shorter LTR than the control subjects, we therefore performed an ROC analysis between the CD8+CD28+/CD8+CD28- ratio and the LTR. Reassuringly, statistical significance was found for the initial CD8+CD28+CD8+CD28- ratio count, the CD8+CD28- T cell count, and the CD8+CD28+CD8+CD28- ratio for predicting the subsequent active stage for the complicated and control CD patients, verifying the effectiveness of this predictive model. The greatest efficiency was found for the CD8+CD28+CD8+CD28- ratio, with a sizable AUC of 0.890, which was significantly larger than CD8+CD28+ or CD8+CD28- T cells alone. More importantly, the greatest sensitivity (89.26%) and specificity (85.32%) were found when the ratio was 1.03, indicating the key time when we should take action to treat CD patients, which is novel in the prediction model field.

Regarding the underlying mechanism for the shift in CD8+ T cell ratios during follow-up, our contention is that there are 2 “shifts” in vivo that are relevant to the dynamic changes in CD8+ T cells and their balance: shifts from blood to colon as well as from CD8+CD28+ to CD8+CD28- T cells. The speeds of CD8+CD28+ T cell increase and CD8+CD28- T cell decrease are not synchronous, and thus the ratio more sensitively reflects the state of immunity than do the 2 T cell populations alone. This hypothesis supports the phenomenon of decreased peripheral blood CD8+CD28+ T cells as well increased CD8+CD28+ T cells in complicated CD patients. Based on this analysis, we speculated that the initial CD8+CD28+/CD8+CD28- ratio could be a sensitive biomarker that can predict a poor outcome for the patients with complicated CD.

4.4. The CD8+CD28+/CD8+CD28- balance is correlated with risk factors

To complete the link between immunity and clinical phenotypes,[36] we performed correlation analysis on the CD8+CD28+/CD8+CD28- ratio and the risk factors, and we found that this ratio was associated with BMI, CDAI, steroids, and surgery. It is possible that a low body weight means a poor nourishment state, and thus weakened immunity, which contributes to higher CD activation.[41] Because steroid use and surgery are the main therapeutic measures and are binary variables, we subgrouped the CD patients according to undergoing steroid/surgery status. We were somewhat surprised that the CD8+CD28+/CD8+CD28- ratios were significantly lower in the steroid and surgery groups than in the nonsteroid and nonsurgery groups, superficially indicating that steroids and surgery are the risk factors for CD patients. Is this true? Many reports have verified that long-term and high-dose administration of steroids can significantly increase opportunistic infections in IBD patients,[42] although surgery can directly remove the inflammatory foci, CD pathogenesis, and especially the underlying immunologic dysfunction, is not yet completely understood.[43] Thus, some CD patients experienced recurrence after surgery, and 2 of 8 subjects in our study suffered from relapse with 30 weeks after intestinal resection (1 subject was administered prednisone at a dose of 50 mg/day before being definitively diagnosed with CD). These data suggest that steroids and surgery are double-edged.
swords and that the immune state is the key factor that is closely associated with recurrence.

Because the CRLRs can confirm comparisons of different risk factors, we performed a Kaplan-Meier analysis and found that CRLRs were also significantly lower in the steroid and surgery CD group when compared to the nonsteroid and nonsurgery group, which is also consistent with the comparison of the CD8+CD28+/CD8+CD28− ratio, suggesting that the CD8+ T cell balance is closely related to the outcome in CD patients. As a consequence, the CD8+CD28+/CD8+CD28− ratio is correlated not only with pathogenesis but also with the therapeutic response.

4.5. Conclusion and clinical significance of this study

For patients with complicated CD, depending on steroids and surgery represents more severe disease activity and thus a disequilibrated immunological balance; thus, treatment with steroids or surgery should be initiated cautiously. Based on our study, we believe that the CD8+CD28+/CD8+CD28− balance is a novel biomarker of CD, with high sensitivity and specificity to predict the active stage for complicated CD patients. In addition, this ratio was also related to curative outcome. More clinically, when the ratio is <1.03, CD patients should follow-up more frequently so that physicians can evaluate their physical and therapeutic state to lessen the possibility of relapse. Our study has 2 main limitations: the sample size and the length of follow-up. Sixty-five subjects is a small number, and we could not avoid bias; thus, more complicated CD patients should be enrolled. A 30-week follow-up is a relatively short time period, and some long-term clinical manifestations cannot be observed during this window, especially for patients who undergo BA treatments >6 times. Moreover, however CD8+CD28+ T cells, CD8+CD28− T cells, and the CD8+CD28+/CD8+CD28− ratio are involved in the development of complicated CD still remains obscure and requires further investigation.

Acknowledgments

The authors thank Professor Ye Chen, Department of Gastroenterology, and Professor Xu Li, Department of Infectious Disease, Nanfang Hospital, Southern Medical University, for their crucial suggestions in the design of this program. The authors also appreciate Xiao-juan Wu (now in the Department of Laboratory Medicine, West China Hospital, Sichuan University) and Chun-yang Wang, Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, for their dedicated work on flow cytometry for CD8+ T cell detection.

References

[1] Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol 2015;31:337–62.
[2] Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology 2013;145:158–65.
[3] Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet 2017;389:1710–9.
[4] Allez M, Mayer L. Regulatory T cells: peace keepers in the gut. Inflamm Bowel Dis 2004;10:666–76.
[5] Dai SX, Wu G, Zou Y, et al. Balance of CD8+CD28+CD8+CD28− T lymphocytes is vital for patients with ulcerative colitis. Dig Dis Sci 2013;58:88–96.
[6] Bioping G, Lugering N, Lutke-Brinstrup S, et al. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells. Clin Exp Immunol 2001;123:15–22.
[7] Dai SX, Gu HY, Lin QY, et al. Disequilibrium in the CD8+CD28+/CD8+CD28− T lymphocyte balance is related to prognosis in rats with trinitrobenzenesulfonic acid-induced colitis. Dig Dis Sci 2017;62:639–51.
[8] Chaciu KA, Osterman MT. How to diagnose and treat IBD mimics in the refractory IBD patient who does not have IBD. Inflamm Bowel Dis 2016;22:1262–74.
[9] Killeen S, Gunn J, Hartley J. Surgical management of complicated and medically refractory inflammatory bowel disease during pregnancy. Colorectal Dis 2017;19:123–38.
[10] Shim TS. Diagnosis and treatment of latent tuberculosis infection in patients with inflammatory bowel diseases due to initiation of anti-tumor necrosis factor therapy. Intest Res 2014;12:12–9.
[11] Sasidharan S, Yajnik V, Khalili H, et al. Genetic risk factors for serious infections in inflammatory bowel diseases. Scand J Gastroenterol 2017;52:570–6.
[12] Abegunde AT, Muhammad BH, Bhatti O, et al. Environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol 2016;22:6296.
[13] Yamagata K, Tanaka M, Kudo H. A quantitative immunohistochemical evaluation of inflammatory cells at the affected and unaffected sites of inflammatory bowel disease. J Gastroenterol Hepatol 1998;13:801–8.
[14] Rieder F, Zimmermann EM, Remzi FH, et al. Crohn’s disease complicated by strictures: a systematic review. Gut 2013;62:1072–84.
[15] Li X, Song P, Li J, et al. The disease burden and clinical characteristics of inflammatory bowel disease in the chinese population: a systematic review and meta-analysis. Int J Environ Res Public Health 2017;14:238.
[16] M’Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol 2013;6:33–47.
[17] Princip M, Giorgio F, Losordo G, et al. Fibrogenesis and fibrosis in inflammatory bowel diseases: good and bad side of same coin? World J Gastroenterol Pathophysiol 2013;4:100–7.
[18] Ahmed I, Roy B, Khan S, et al. Microbiome, metabolome and inflammatory bowel disease. Microorganisms 2016;4:20.
[19] Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015;12:205.
[20] Burisch J, Pedersen N, Đaković-Slavka S, et al. East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpIC inception cohort. Gut 2014;63:588–97.
[21] Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978–2002. Eur J Gastroenterol Hepatol 2006;18:601–6.
[22] John ES, Katz K, Saxena M, et al. Management of inflammatory bowel disease in the elderly. Curr Treat Options Gastroenterol 2016;14:285–304.
[23] Lichtenstein FR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409–22.
[24] Chapman CG, Yamaguchi K, Tamura K, et al. Characterization of T-cell receptor repertoire in inflamed tissues of patients with Crohn’s disease through deep sequencing. Inflamm Bowel Dis 2016;22:1275–85.
[25] Campbell NA, Park MS, Toy LS, et al. A non-class I MHC intestinal epithelial surface glycoprotein, gp180, binds to CD8. Clin Immunol 2002;102:267–74.
[26] Mayer L, Shlien R. Evidence for function of la molecules on gut epithelial cells in man. J Exp Med 1987;166:1471–83.
[27] Brandes JM, Sayegh MH, Gallon L, et al. Rat intestinal epithelial cells present major histocompatibility complex allopeptides to primed T cells. Gastroenterology 1994;107:1537–42.
[28] Cortesini R, LeMaoul C, Ciubotaru R, et al. CD8+CD28− T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 2001;182:201–6.
[29] Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990;86:1255–60.
[30] Allez M, Brimnes J, Shao L, et al. Activation of a unique population of CD8(+) T cells by intestinal epithelial cells. Ann N Y Acad Sci 2004;1029:22–35.
[31] Das G, Augustine MM, Das J, et al. An important regulatory role for CD4+CD8 alpha T cells in the intestinal epithelial layer in the
prevention of inflammatory bowel disease. Proc Natl Acad Sci U S A 2003;100:5324–9.

[32] Poussier P, Ning T, Banerjee D, et al. A unique subset of self-specific intraintestinal T Cells maintains gut integrity. J Exp Med 2002;195:1491–7.

[33] Tom MR, Li J, Ueno A, et al. Novel CD8+ T-cell subsets demonstrating plasticity in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:1596–608.

[34] Van Der Sloot KW, Joshi AD, Bellavance DR, et al. Visceral adiposity, genetic susceptibility, and risk of complications among individuals with Crohn’s disease. Inflamm Bowel Dis 2017;23:828–38.

[35] Brimnes J, Allez M, Dotan I, et al. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 2005;174:3814–22.

[36] Funderburg NT, Stubblefield Park SR, Sung HC, et al. Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 2013;140:87–97.

[37] Lemmens B, de Buck van Overstraeten A, Arijs I, et al. Submucosal plexitis as a predictive factor for postoperative endoscopic recurrence in patients with Crohn’s disease undergoing a resection with ileocolonic anastomosis: results from a prospective single-centre study. J Crohns Colitis 2017;11:212–20.

[38] Sahami S, Bartels SAL, D’Hoore A, et al. External validation of a prognostic model of preoperative risk factors for failure of restorative proctocolectomy. Colorectal Dis 2017;19:181–7.

[39] Rinawi F, Assa A, Hartman C, et al. Incidence of bowel surgery and associated risk factors in pediatric-onset Crohn’s disease. Inflamm Bowel Dis 2016;22:2917–23.

[40] Gibson DJ, Ryan EJ, Doherty GA. Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2716–24.

[41] Heerasing N, Thompson B, Hendy P, et al. Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn’s disease. Aliment Pharmacol Ther 2017;45:660–9.

[42] Ong MS, Grand RJ, Mandl KD. Trends in pharmacologic interventions for preventing recurrence of Crohn’s disease after ileocolonic surgery. Inflamm Bowel Dis 2016;22:2432–41.

[43] Maguire LH, Alavi K, Sudan R, et al. Surgical considerations in the treatment of small bowel Crohn’s disease. J Gastrointest Surg 2017;21:398–411.